Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.

IF 5.4 2区医学 Q1 ALLERGY

Current Allergy and Asthma Reports Pub Date : 2024-02-01 Epub Date: 2024-01-18 DOI:10.1007/s11882-024-01128-y

Dayne Voelker, Thanai Pongdee

{"title":"Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.","authors":"Dayne Voelker, Thanai Pongdee","doi":"10.1007/s11882-024-01128-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Mast cell activation syndrome is defined by severe, episodic, and recurrent symptoms induced by mast cell mediators with objective measurement of increase in biomarkers of mast cell activation and treatment response with mast cell therapies. Increase in serum tryptase from baseline during a mast cell activation episode is currently the most accepted biomarker measurement of mast cell release. However, during symptomatic episodes, serum tryptase can be difficult to obtain as it is a venipuncture procedure. Other objective measures of mast cell activation are needed to complement serum tryptase.Recent findings: Urine mast cell mediators can be collected at home and are non-invasive tests. There is emerging evidence for the utility of urine mast cell mediators including histamine, cysteinyl leukotrienes, and prostaglandins in the diagnosis of mast cell activation syndrome. In this review, clinically available urine mast cell mediators will be discussed including N-methylhistamine, leukotriene E4, and 2,3-dinor-11beta-prostaglandin F2 alpha. We discuss the rationale for the use of these urine mast cell mediators and examine the studies analyzing their performance for identifying mast cell activation.","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"33-38"},"PeriodicalIF":5.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-024-01128-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Mast cell activation syndrome is defined by severe, episodic, and recurrent symptoms induced by mast cell mediators with objective measurement of increase in biomarkers of mast cell activation and treatment response with mast cell therapies. Increase in serum tryptase from baseline during a mast cell activation episode is currently the most accepted biomarker measurement of mast cell release. However, during symptomatic episodes, serum tryptase can be difficult to obtain as it is a venipuncture procedure. Other objective measures of mast cell activation are needed to complement serum tryptase.

Recent findings: Urine mast cell mediators can be collected at home and are non-invasive tests. There is emerging evidence for the utility of urine mast cell mediators including histamine, cysteinyl leukotrienes, and prostaglandins in the diagnosis of mast cell activation syndrome. In this review, clinically available urine mast cell mediators will be discussed including N-methylhistamine, leukotriene E4, and 2,3-dinor-11beta-prostaglandin F2 alpha. We discuss the rationale for the use of these urine mast cell mediators and examine the studies analyzing their performance for identifying mast cell activation.

Abstract Image

查看原文本刊更多论文

评估和诊断肥大细胞活化综合征的尿液肥大细胞介质。

综述的目的：肥大细胞活化综合征的定义是由肥大细胞介质诱发的严重、发作性和复发性症状，可客观测量肥大细胞活化生物标志物的增加和肥大细胞疗法的治疗反应。在肥大细胞活化发作期间，血清胰蛋白酶从基线升高是目前最被接受的肥大细胞释放生物标志物测量方法。然而，在症状发作期间，由于需要进行静脉穿刺，因此很难获得血清胰蛋白酶。因此需要其他肥大细胞活化的客观指标来补充血清胰蛋白酶：尿液肥大细胞介质可在家中收集，是一种非侵入性检测。尿液肥大细胞介质（包括组胺、半胱氨酸白三烯和前列腺素）在肥大细胞活化综合征诊断中的实用性已有新的证据。本综述将讨论临床可用的尿液肥大细胞介质，包括 N-甲基组胺、白三烯 E4 和 2,3-二去甲-11beta-前列腺素 F2 alpha。我们将讨论使用这些尿液肥大细胞介质的理由，并研究分析这些介质在识别肥大细胞活化方面的性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Allergy and Asthma Reports 医学-过敏

CiteScore

11.20

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.